Coca-Cola Consolidated, Inc.
COKE
$192.04
+2.63%
Coca-Cola Consolidated, Inc. is the largest independent bottler and distributor of Coca-Cola products in the United States, manufacturing, marketing, and distributing a broad portfolio of nonalcoholic beverages that spans sparkling carbonated drinks, bottled water, ready-to-drink tea and coffee, enhanced water, juices, sports drinks, and energy products across two reporting segments: Nonalcoholic Beverages and All Other. Unlike The Coca-Cola Company, which owns the concentrate and brand IP, COKE operates as a capital-intensive franchise bottler with exclusive territorial rights, giving it a distinct but lower-margin position within the Coca-Cola system and a competitive moat rooted in distribution density rather than brand ownership. The current investor narrative centers on a powerful multi-year margin-expansion and capital-return story: the company has been aggressively buying back stock (roughly $2.46 billion repurchased in Q4 2025 alone), deleveraging its balance sheet, and posting double-digit revenue growth, which has driven the shares up roughly 67% over the past year and far outpaced the S&P 500. Debate among investors now hinges on whether these operational gains are sustainable or whether the stock has become overextended after such a sharp run, particularly given the recent pullback from its 52-week high and the company's negative book equity from sustained buybacks.…
COKE
Coca-Cola Consolidated, Inc.
$192.04
Investment Opinion: Should I buy COKE Today?
The synthesized recommendation is Hold. The core thesis is that COKE is a well-managed, cash-generative bottler with accelerating revenue and a shareholder-friendly capital return program, but the stock's 67% one-year rally has already priced in much of the good news, and the lack of analyst consensus (only one analyst, no target) makes it difficult to justify a Buy at current levels. The recent six-month underperformance versus the S&P 500 (-16.69 percentage points) and net margin compression to 6.04% warrant caution. Supporting evidence includes: 1) Revenue growth of 16.88% YoY in Q1 2026, up from 9.03% in Q4 2025; 2) Gross margin stable at 39.37%, demonstrating pricing power; 3) Trailing free cash flow of $662.1 million with a low dividend payout ratio of 15.19%; 4) Aggressive buybacks reducing shares outstanding from 87.4 million to 56.5 million year-over-year; and 5) A defensive beta of 0.547. However, valuation is not compelling: trailing PE of 19.78x is mid-to-upper in its historical 10x-29x range, PEG of 1.87 is above 1, and EV/EBITDA of 13.55x is full. The biggest risks that could invalidate the thesis are: 1) Revenue growth decelerating below 10%, which would pressure the premium multiple; 2) Net margin remaining below 7% due to high interest expense; and 3) A broader market rotation away from defensive staples. The rating would upgrade to Buy if the stock pulls back to the $163-$170 support zone (implying a PE near 17x) or if revenue growth sustains above 15% for two more quarters. It would downgrade to Sell if revenue growth falls below 5% or if free cash flow declines below $500 million. Relative to its history and peers, COKE appears fairly valued to slightly overvalued, with the market pricing in continued operational improvements.
Sign up to view all
COKE 12-Month Price Forecast
COKE presents a balanced risk/reward at current levels. The company's operational momentum is strong, with accelerating revenue and stable gross margins, but the stock has already rallied 67% over the past year and now trades at a full valuation with negative book equity and compressed net margins. The lack of analyst coverage means there is no consensus target to anchor expectations, and the recent six-month underperformance versus the S&P 500 suggests the market is digesting the gains. I would upgrade to bullish if revenue growth sustains above 15% for two more quarters and net margin recovers above 7%, or if the stock pulls back to the $163-$170 support zone. I would downgrade to bearish if revenue growth falls below 5% or if free cash flow declines below $500 million, which would likely trigger multiple compression.
Wall Street consensus
Insufficient analyst coverage available. Only 1 analyst is reported as covering COKE, with a recommendation of "none" and no consensus target price, estimated EPS, or Buy/Hold/Sell distribution provided; the estimated revenue average of $7.228 billion is the sole forward-looking estimate available. This extremely thin coverage is characteristic of a mid-cap, family-controlled bottler with a limited float and low institutional ownership relative to mega-cap staples peers, and it means there is no meaningful consensus target against which to calculate implied upside or downside from the current $190.29 price.
The absence of robust analyst coverage has important implications for investors. With no published target range, there is no high-target scenario to gauge bull-case assumptions (e.g., multiple expansion or accelerating growth) nor a low-target scenario to frame bear-case risks (e.g., margin compression or volume declines), leaving price discovery to a thinner pool of market participants. The institutional ratings history is stale — the most recent action is a Citigroup "Neutral" reiteration from May 2016, with all prior ratings also Neutral dating back to 2012 — indicating that sell-side engagement has been minimal for nearly a decade. For investors, this limited coverage typically translates into higher idiosyncratic volatility, wider bid-ask spreads, and less efficient pricing, meaning fundamental research and independent valuation work are especially important when evaluating COKE.
Bulls vs Bears: COKE Investment Factors
The bull case currently has stronger evidence, anchored by accelerating revenue growth (16.88% YoY), stable gross margins near 39-40%, and massive buybacks that have reduced shares outstanding by over 35% in a year. However, the bear case is gaining traction: net margin compression to 6.04%, negative book equity, and a -16.69 percentage point relative-strength gap over six months suggest the stock may have run ahead of fundamentals. The single most important tension is whether the Q1 2026 revenue acceleration is sustainable or a one-time step-up; if growth decelerates back to the 6-9% range, the stock's premium valuation and thin analyst coverage could amplify downside. Conversely, if margin expansion resumes and buybacks continue, the stock could re-rate higher despite recent underperformance.
Bullish
- Revenue growth accelerated to 16.9% YoY: Q1 2026 revenue of $1.847 billion grew 16.88% year-over-year, a notable step-up from Q4 2025's 9.03% and Q3 2025's 6.95% growth rates. This acceleration suggests the company is gaining volume or pricing traction despite operating in a mature, concentrated category.
- Gross margin stable near 39-40%: Gross margin has held remarkably steady at 39.37% in Q1 2026, 38.21% in Q4 2025, 39.64% in Q3 2025, and 40.02% in Q2 2025. This consistency demonstrates pricing power and cost discipline in a capital-intensive bottling model.
- Massive buyback reduces share count: The company repurchased roughly $2.46 billion of stock in Q4 2025 alone, shrinking shares outstanding from 87.4 million in Q4 2024 to 56.5 million in Q1 2026. This aggressive capital return amplifies per-share earnings growth and signals management's confidence in intrinsic value.
- Strong free cash flow and low payout: Trailing free cash flow is $662.1 million, comfortably covering the $16.6 million quarterly dividend with a payout ratio of just 15.19%. The 0.77% dividend yield is modest but sustainable, leaving ample room for continued buybacks or debt reduction.
Bearish
- Negative book equity from buybacks: Debt-to-equity is -4.06 and price-to-book is -15.26, both artifacts of negative shareholders' equity driven by sustained buybacks. This makes traditional leverage and book-value metrics meaningless and signals reliance on credit markets rather than a fortress balance sheet.
- Net margin compressed to 6.04%: Q1 2026 net margin fell to 6.04% from a peak of 10.10% in Q2 2025, largely due to interest expense rising to $32.1 million from $5.9 million. This earnings volatility highlights sensitivity to financing costs and one-time items.
- Recent underperformance vs. S&P 500: Over the past six months, COKE gained just 4.96% versus the S&P 500's 21.65%, a -16.69 percentage point relative-strength gap. The stock is down 1.92% over the past month, indicating a loss of leadership and potential mean reversion.
- Thin analyst coverage and no consensus: Only one analyst covers COKE, with no recommendation or target price provided. This lack of sell-side engagement since 2016 implies inefficient pricing, wider spreads, and higher idiosyncratic volatility.
COKE Technical Analysis
COKE is in a sustained longer-term uptrend that has cooled into a choppy consolidation phase. The stock is up 67.02% over the trailing year and 27.00% year-to-date, dramatically outperforming the S&P 500's 17.22% and 13.11% respective gains, with a relative strength of +49.80 percentage points versus the index over 12 months. At a current price of $190.29, the shares sit at roughly 73% of the 52-week range (52-week low of $113.97, high of $219.65), meaning they are in the upper half of the band but about 13.4% below the high — a positioning that reflects strong residual momentum but also a market that has already priced in much of the good news. The 24.66% maximum drawdown over the period confirms this is not a one-way trade and that volatility has been meaningful even within the uptrend.
Short-term momentum has clearly decelerated and now diverges from the powerful yearly trend. The stock is down 1.92% over the past month and up only 1.20% over three months, badly lagging the S&P 500's +0.69% and +5.81% over the same windows, producing negative relative strength of -2.61 and -4.61 percentage points for the 1- and 3-month periods. The 6-month picture is even more telling: COKE is up just 4.96% versus the S&P's 21.65%, a -16.69 point relative-strength gap that signals a clear loss of leadership since spring 2026. This divergence — a strong 1-year trend colliding with flat-to-negative recent performance — suggests the stock is digesting its massive run through a period of mean reversion or base-building rather than a clean trend reversal, though the persistent underperformance versus the index warrants caution.
Key technical levels are well defined by the 52-week range. Support sits near the $113.97 52-week low, with intermediate support around the $163–$170 zone where the stock bottomed in May 2026; resistance is anchored at the $219.65 52-week high, with the $200–$205 area acting as near-term overhead supply given repeated failures there in September. A decisive breakout above $219.65 would reassert the primary uptrend and likely draw momentum buyers, while a breakdown below the $163–$170 support shelf would signal a deeper corrective phase and put the 52-week low in play. Notably, COKE's beta of just 0.547 means it is roughly 45% less volatile than the broad market, a defensive characteristic that supports smaller position-sizing adjustments for risk but also explains why the stock has lagged a rising tape; the short ratio of 6.14 days-to-cover indicates a modest but non-trivial short base that could amplify upside on a breakout.
Beta
0.55
0.55x market volatility
Max Drawdown
-24.7%
Largest decline past year
52-Week Range
$118-$220
Price range past year
Annual Return
+61.0%
Cumulative gain past year
| Period | COKE Return | S&P 500 |
|---|---|---|
| 1m | -1.6% | +0.6% |
| 3m | -1.8% | +3.3% |
| 6m | -1.4% | +17.4% |
| 1y | +61.0% | +15.0% |
| ytd | +28.2% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
COKE Fundamental Analysis
COKE's revenue trajectory remains solidly positive, with the most recent quarter (Q1 2026, ended April 3, 2026) delivering $1.847 billion in revenue, up 16.88% year-over-year from $1.580 billion in Q1 2025. The multi-quarter trend shows healthy but moderating growth: Q4 2025 revenue of $1.904 billion rose 9.03% from $1.746 billion in Q4 2024, while Q3 2025's $1.888 billion grew 6.95% from $1.766 billion a year earlier, indicating that the Q1 2026 acceleration was a notable step-up rather than a steady cadence. Segment data shows the Nonalcoholic Beverage segment generated $1.834 billion versus just $89.5 million from the All Other segment, confirming that essentially the entire business — and therefore all growth — is driven by the core bottling operation, leaving the company highly concentrated in a single, mature category where pricing power and volume mix are the primary growth levers.
Profitability is robust and margins are holding at attractive levels. Q1 2026 net income was $111.6 million on a 6.04% net margin, with gross profit of $727.1 million representing a 39.37% gross margin and operating income of $237.5 million (12.86% operating margin). Comparing sequentially, gross margin has been remarkably stable — 39.37% in Q1 2026, 38.21% in Q4 2025, 39.64% in Q3 2025, and 40.02% in Q2 2025 — while net margin has compressed modestly from the 10.10% peak in Q2 2025 to 6.04% in Q1 2026, largely reflecting higher interest expense ($32.1 million in Q1 2026 versus $5.9 million in Q2 2025) and a lower operating-income ratio (12.86% versus 14.66%). The company's trailing net margin of 7.89% and operating margin of 13.15% are respectable for a capital-intensive bottler, though the Q1 2026 net income of $111.6 million was down from $187.4 million in Q2 2025, underscoring that earnings are cyclical and sensitive to interest costs and one-time items.
Balance-sheet and cash-flow metrics present a mixed but generally improving picture. The company generated $662.1 million in trailing free cash flow and $205.3 million in operating cash flow in Q1 2026 against $63.1 million of capital expenditure, comfortably funding its $16.6 million quarterly dividend (payout ratio of just 15.19%, dividend yield 0.77%). However, the balance sheet carries meaningful leverage: the debt-to-equity ratio is deeply negative at -4.06 and the price-to-book ratio is -15.26, both artifacts of negative shareholders' equity driven by aggressive buybacks (including $2.46 billion of stock repurchased in Q4 2025), which makes traditional leverage and book-value metrics difficult to interpret. Liquidity is adequate with a current ratio of 1.26, and the interest coverage ratio of 7.41x is healthy, but the cash-flow-to-debt ratio of just 0.075 and the negative equity position mean the company relies on internally generated cash and continued access to credit markets rather than a fortress balance sheet — a risk factor worth monitoring even as ROA of 12.46% demonstrates efficient asset utilization.
Quarterly Revenue
$2.1B
2026-07
Revenue YoY Growth
+10.6%
YoY Comparison
Gross Margin
37.9%
Latest Quarter
Free Cash Flow
$644707000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is COKE Overvalued?
Because COKE is profitable — Q1 2026 net income of $111.6 million and trailing EPS of $0.0505 — the appropriate primary metric is the price-to-earnings ratio. The stock trades at a trailing PE of 19.78x, but the forward PE of just 4.89x is extraordinarily low, implying the market expects a massive earnings step-up; this enormous gap between trailing and forward multiples suggests either a data anomaly (the trailing EPS figure of $0.0505 appears inconsistent with quarterly diluted EPS of $1.67–$1.97) or a market pricing in a dramatic profit inflection. On a price-to-sales basis, COKE trades at 1.56x, and its EV/EBITDA of 13.55x and EV/Sales of 1.96x provide additional reference points for a capital-intensive distributor.
Peer comparison within the Consumer Defensive / Beverages-Non-Alcoholic sector shows COKE trading at a discount on some measures and a premium on others. The PS ratio of 1.56x is low in absolute terms for a branded beverage distributor, and the trailing PE of 19.78x is roughly in line with or below the broader consumer staples sector, which often trades in the low-to-mid 20s. However, the price-to-cash-flow ratio of 12.05x and the PEG ratio of 1.87 suggest the stock is not cheap relative to its growth rate, and the EV/EBITDA of 13.55x is a full multiple for a bottler with single-digit-to-mid-teens revenue growth. The negative PB ratio of -15.26 makes book-value comparisons meaningless, so investors must rely on earnings- and cash-flow-based multiples, where COKE screens as reasonably valued but not a bargain.
Historically, COKE's valuation has expanded significantly. The PE ratio has ranged from roughly 10.1x (Q4 2022) to 28.7x (Q4 2023), and the PS ratio has climbed from about 2.37x in Q3 2022 to 5.96x in Q1 2026 — though the current reported PS of 1.56x appears to reflect a different share-count or data basis than the historical series. The stock's historical PE band of roughly 10x–29x places the current 19.78x in the middle-to-upper portion of its own range, suggesting the market is pricing in solid but not euphoric expectations. The forward PE of 4.89x, if accurate, would represent a dramatic compression from historical norms and would imply the stock is deeply undervalued on forward earnings — a signal that warrants verification given the inconsistency in the underlying EPS data.
PE
19.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the company's negative shareholders' equity and reliance on debt. The debt-to-equity ratio of -4.06 and price-to-book of -15.26 reflect aggressive buybacks ($2.46 billion in Q4 2025 alone) that have eroded book value, making traditional leverage metrics uninterpretable. Interest expense surged to $32.1 million in Q1 2026 from $5.9 million in Q2 2025, directly compressing net margin to 6.04% from 10.10%. Additionally, the cash-flow-to-debt ratio of just 0.075 indicates limited cushion if operating cash flow declines, and the business is highly concentrated in the Nonalcoholic Beverages segment ($1.834 billion of $1.847 billion revenue), leaving little diversification. Market and competitive risks include valuation compression and sector rotation. The stock trades at a trailing PE of 19.78x and EV/EBITDA of 13.55x, which is full for a bottler with mid-teens growth, and the PEG of 1.87 suggests it is not cheap relative to growth. With a beta of 0.547, COKE is defensive, but its recent underperformance versus the S&P 500 (-16.69 percentage points over six months) signals that investors may be rotating into higher-beta growth names. Thin analyst coverage (only one analyst, no consensus target) exacerbates pricing inefficiency and could lead to sharper drawdowns if sentiment shifts. The worst-case scenario involves a combination of revenue deceleration, margin compression, and multiple contraction. If Q1 2026's 16.88% growth proves unsustainable and reverts to the 6-9% range, and interest expense remains elevated, net margin could fall below 5%, pressuring earnings. A re-rating to the lower end of its historical PE band (10x) would imply a significant downside; from the current price of $190.29, a drop to the 52-week low of $113.97 represents a -40.1% loss. Even a move to the May 2026 support zone of $163-$170 would mean a -10.7% to -14.3% decline. Given the negative book equity and thin coverage, a worst-case scenario could see the stock test $114, especially if buybacks slow or credit conditions tighten.
FAQ
The key risks are ranked as follows: 1) Financial risk: Negative shareholders' equity (debt-to-equity of -4.06) and a cash-flow-to-debt ratio of just 0.075 mean the company relies on credit markets and internal cash, with limited cushion if cash flow declines. 2) Earnings volatility: Net margin compressed to 6.04% in Q1 2026 from 10.10% in Q2 2025, driven by interest expense rising to $32.1 million, and further increases could pressure profitability. 3) Competitive/market risk: The company is highly concentrated in the Nonalcoholic Beverages segment ($1.834 billion of $1.847 billion revenue), leaving it vulnerable to shifts in consumer preferences or loss of a key distribution agreement. 4) Valuation risk: With a PEG of 1.87 and EV/EBITDA of 13.55x, the stock could suffer multiple compression if growth decelerates, especially given thin analyst coverage and a -16.69 percentage point six-month relative-strength gap versus the S&P 500.
The 12-month forecast has three scenarios: Bull case (25% probability) targets $220-$240, assuming revenue growth stays above 15%, net margin recovers above 7%, and buybacks continue. Base case (55% probability) targets $180-$210, assuming revenue growth moderates to 8-12% and margins stabilize. Bear case (20% probability) targets $114-$160, assuming revenue growth falls below 5%, interest expense remains high, and multiple compresses. The base case is most likely, hinging on whether Q1 2026's 16.88% revenue growth is sustainable or a one-time step-up. Given the stock's current price of $190.29, the base case implies roughly flat to modest upside, while the bear case represents a -16% to -40% downside. The lack of analyst targets makes these scenarios more uncertain than usual.
COKE appears fairly valued to slightly overvalued. Its trailing PE of 19.78x sits in the middle-to-upper portion of its historical 10x-29x range, while the PEG ratio of 1.87 is above 1, indicating the stock is not cheap relative to its growth rate. The EV/EBITDA of 13.55x is a full multiple for a capital-intensive bottler with mid-teens revenue growth. On the positive side, the PS ratio of 1.56x is low in absolute terms, and the forward PE of 4.89x—if accurate—would imply deep undervaluation, but this figure appears inconsistent with reported EPS and warrants verification. The negative price-to-book of -15.26 makes book-value comparisons meaningless. Overall, the market is pricing in continued operational improvements and buyback-driven EPS growth, leaving limited margin for error.
COKE is a good buy only for specific investors and at the right price. The stock has strong fundamentals: 16.88% revenue growth in Q1 2026, stable 39.37% gross margins, and $662.1 million in trailing free cash flow. However, it trades at a trailing PE of 19.78x with a PEG of 1.87, and the lack of analyst consensus (only one analyst, no target) makes it hard to gauge upside. The biggest downside risk is a reversion to the 52-week low of $113.97, representing a -40% loss. For long-term investors comfortable with a low-beta, defensive holding, COKE is a reasonable buy on pullbacks to the $163-$170 support zone. For short-term traders, the recent underperformance versus the S&P 500 (-16.69 percentage points over six months) suggests waiting for a clearer trend.
COKE is better suited for long-term investment than short-term trading. The company is a mature, capital-intensive bottler with a low beta of 0.547, a modest dividend yield of 0.77%, and a dividend payout ratio of just 15.19%, indicating a focus on buybacks over income. Earnings visibility is moderate, with revenue growth fluctuating between 6.95% and 16.88% over the past four quarters, and net margin ranging from 6.04% to 10.10%. Short-term traders face thin analyst coverage, wide bid-ask spreads, and recent underperformance versus the S&P 500. A suggested minimum holding period is 2-3 years to allow the buyback program to compound per-share earnings and for margin trends to normalize. The stock's defensive characteristics make it suitable as a core holding in a conservative portfolio, but not for those seeking high growth or income.